Free Trial

Humacyte (HUMA) News Today

Humacyte logo
$1.31 -0.10 (-7.09%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.31 0.00 (0.00%)
As of 05/2/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Humacyte, Inc. stock logo
Humacyte (HUMA) to Release Earnings on Friday
Humacyte (NASDAQ:HUMA) will be releasing its Q1 2025 earnings before the market opens on Friday, May 9. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-9-humacyte-inc--stock/)
Humacyte Insiders Placed Bullish Bets Worth US$949.4k
Humacyte, Inc. stock logo
Cantor Fitzgerald Increases Earnings Estimates for Humacyte
Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, April 23rd. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.71) per share for
Humacyte, Inc. stock logo
Jump Financial LLC Has $474,000 Holdings in Humacyte, Inc. (NASDAQ:HUMA)
Jump Financial LLC trimmed its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 71.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,763 shares of the company's stock after selling 233,859 shares during the q
Humacyte FY2025 EPS Forecast Increased by Cantor Fitzgerald
Humacyte, Inc. stock logo
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by Analysts
Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have given a buy rating an
Humacyte, Inc. stock logo
Shamik J. Parikh Buys 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock
Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh purchased 7,500 shares of Humacyte stock in a transaction on Thursday, April 10th. The shares were purchased at an average cost of $1.55 per share, with a total value of $11,625.00. Following the transaction, the insider now owns 7,500 shares in the company, valued at approximately $11,625. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Humacyte, Inc. stock logo
Humacyte, Inc. (NASDAQ:HUMA) CFO Dale A. Sander Purchases 20,000 Shares
Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) CFO Dale A. Sander bought 20,000 shares of the company's stock in a transaction on Thursday, April 10th. The stock was purchased at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at approximately $62,118. The trade was a 97.09 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Humacyte, Inc. stock logo
Vanguard Group Inc. Purchases 543,995 Shares of Humacyte, Inc. (NASDAQ:HUMA)
Vanguard Group Inc. increased its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,602,684 shares of the company's stock after acquiring a
Humacyte, Inc. stock logo
Franklin Resources Inc. Takes Position in Humacyte, Inc. (NASDAQ:HUMA)
Franklin Resources Inc. acquired a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 433,482 shares of the company's stock, valued at approximately $2
Humacyte, Inc. stock logo
CenterBook Partners LP Makes New $6.46 Million Investment in Humacyte, Inc. (NASDAQ:HUMA)
CenterBook Partners LP acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,279,839 shares of the company's stock, valued at approximately $6,463,000. CenterBook P
Humacyte, Inc. stock logo
Humacyte, Inc. (NASDAQ:HUMA) Director Purchases $66,000.00 in Stock
Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) Director Kathleen Sebelius purchased 50,000 shares of the stock in a transaction dated Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Humacyte, Inc. stock logo
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by Analysts
Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has is
Humacyte, Inc. stock logo
Thrivent Financial for Lutherans Has $2.10 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)
Thrivent Financial for Lutherans lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 217.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 415,262 shares of the company's stock after buying an additional 284,
Humacyte, Inc. stock logo
Humacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS
Humacyte (NASDAQ:HUMA - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.08.
Humacyte, Inc. stock logo
Humacyte (NASDAQ:HUMA) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS
Humacyte (NASDAQ:HUMA - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.08.
Humacyte price target lowered to $8 from $10 at BTIG
Humacyte, Inc. stock logo
D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)
D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Wednesday.
Humacyte stock plunges on public offering pricing
Humacyte 25M share Spot Secondary priced at $2.00
Humacyte, Inc. stock logo
Humacyte (HUMA) Projected to Post Earnings on Friday
Humacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, March 28, Financial Modeling Prep reports.
Humacyte, Inc. stock logo
Humacyte's (HUMA) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research report on Wednesday.
Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.

HUMA Media Mentions By Week

HUMA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HUMA
News Sentiment

0.79

0.73

Average
Medical
News Sentiment

HUMA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HUMA Articles
This Week

3

10

HUMA Articles
Average Week

Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:HUMA) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners